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Inﬂammatory or anti-inﬂammatory? That is the question as far as the acute-phase response and its mediators, the pentraxins, are
concerned. Only some ten years ago, the classical or short pentraxin C-reactive protein and the newly discovered long pentraxin
PTX3 were considered to exert most of the detrimental eﬀects of acute inﬂammation, whether microbial or sterile in origin.
However, accumulating evidence suggests an at least dichotomous, context-dependent outcome attributable to the pentraxins,
if not a straightforward anti-inﬂammatory nature of the acute-phase response. This paper is focused on the inherent eﬀects of
pentraxin3ininﬂammatoryresponses,mainlyincoronaryarterydiseaseandinAspergillusfumigatusinfection.Bothareexamples
of inﬂammatory reactions in which PTX3 is substantially involved; the former sterile, the latter infectious in origin. Apart from
diﬀerent inducing noxae, similarities in the pathogenesis of the two are striking. All the same, the introductory question still
persists: is the ultimate impact of PTX3 in these conditions inﬂammatory or anti-inﬂammatory, paradoxical as the latter might
appear? We try to provide an answer such as it emerges in the light of recent ﬁndings.
1. Danger Recognition
The innate immune system provides the ﬁrst line of defense
against microorganisms with which humans are daily con-
tacted. The encounter with the microbial world occurs either
on the body’s external surface, that is, on the skin, or on its
internal (mucosal) surfaces in the airways and in the gastro-
intestinal tract. The vast majority of these steady-contact
microbes are not inherently pathogenic. Nevertheless, their
eventual threat to the host may vary considerably according
to both external/environmental and to internal conditions,
the latter being reﬂected by the ability of the host to mount
a na p p r o p r i a t ei m m u n er e s p o n s e .W h e n e v e rn e e d e d ,t h i sr e -
sponse must go on to involve the adaptive immune reac-
tion(s).Basically,thesameholdstrueforvirtuallypathogenic
microorganisms. An infection may be brought right under
control if confronted with an immunologically competent
host. Actually, the net result of pathogen-host interaction,
that is, whether health is maintained or disease develops,
relies on the balance between pathogen virulence and the
capacity of the individual immune response. The innate and
adaptive immune reactions form a continuum of closely in-
terrelated steps with innumerable positive and negative feed-
back loops. Therefore, they should be viewed as two sides of
the same coin [1].
Toinitiateadefensereaction,ﬁrstofall,amicroorganism
must be sensed and recognized by the immune system as po-
tentially harmful. It has been established that microorgan-
isms are not recognized in their individual complexity. In-
stead, several sets of highly conserved molecular moieties
which are shared by large groups of microorganisms are
implicated in the process of being recognized. These molec-
ular motifs, collectively referred to as alarmins or pathogen-
associated molecular patterns (PAMPs), are committed to2 Mediators of Inﬂammation
elicitadangersignal withintheimmunesystem.Importantly,
closely resembling or even identical molecular structures are
present in the host’s own cells. Under normal conditions,
thesemoleculesarewellhiddeninsidethecellularcytoplasm,
far beyond the reach of the recognition machinery. In cells
undergoing apoptotic or necrotic death, the hallmark of
sepsis or ischemia-reperfusion injury, PAMPs/alarmins are
promptlyexposedonthesurfacemembraneofthehost’scells
or even released into the extracellular space [2, 3]. Another
way to exhibit own PAMPs/alarmins, albeit in a slow, gradual
process,occursinlow-gradeinﬂammation.Examplesthereof
are atherogenesis or rheumatoid arthritis. Inﬂammatory dis-
eases which develop in the absence of microorganisms are
called sterile inﬂammation [4].
The constituents of the immune system which are in-
volved in the process of recognizing PAMPs, either of micro-
bial origin in bacteremia/sepsis or modiﬁed self-structuresin
sterile inﬂammation, are represented by germ line-encoded
receptors known as pattern recognition molecules (PRMs).
The occurrence of PRMs is not conﬁned to canonical com-
ponents of the immune system, but other cells are also
involved. From the viewpoint of cardiology/cardiac surgery,
endothelial cells play a prominent role [5].
Within the human body, pattern recognition molecules/
receptors are present either as cell-associated- or as ﬂuid-
phase molecules. The former are localized in most tissues,
whereas the latter are distributed in the liquid compartment,
that is, mainly, but not exclusively, in the blood. Cell-asso-
ciated receptors are made up by endocytic/scavenger recep-
tors, signalling receptors (e.g., toll-like receptors), and nucle-
otide-binding oligomerization domain- (NOD-)like recep-
tors [6]. The ﬂuid-phase molecules represent evolutionary
ancestors of antigen-speciﬁc antibodies. This heterogeneous
group of molecules consists of three clearly deﬁned sub-
groups,thatis,thecollectins,theﬁcolins,andthepentraxins.
All of them are implicated in complement activation, patho-
gen opsonisation, and/or self versus modiﬁed-self versus
non-self discrimination [7].
2. A Brief Glance atthe PentraxinSuperfamily
The pentraxins form a superfamily of multifunctional pro-
teins which have been conserved in phylogeny from arach-
nids to mammals. The pentraxin superfamily is distin-
guished by the presence in their C(carboxy)-terminal region
of a ∼200 amino acid domain containing a highly conserved
motif of 8-amino-acid sequence, which has been named the
pentraxin signature (HxCxS/TWxS, where x is any amino
acid). Based on the primary structure of the protomer, the
pentraxins branch oﬀ into twogroups: the shortconstituents
and their long counterparts [8].
Short pentraxins are about 25-kDa proteins sharing a
common structural organization of ﬁve or ten subunits that
are assembled in pentameric radial symmetry. The classical
short pentraxins C-reactive protein (CRP) and serum amyl-
oid P component (SAP) are acute-phase proteins in humans
and in mice, respectively. They are manufactured in the liver
under the guidance of inﬂammatory cytokines, most promi-
nently of interleukin (IL)-6 and, to a lesser degree, of IL-1β.
CRP is the major acute-phase reactant in humans. Its levels
arescarcelydetectableinplasmaofhealthypersons,inwhom
CRP concentrations do not exceed 3mg/L (3μg/mL). How-
ever, CRP plasma concentrations increase as much as 1000-
fold under inﬂammatory conditions, irrespective whether of
bacterial(sepsis)orsterile(sepsis-like)origin.Classically,the
latter develops in patients after trauma and surgical opera-
tions or in patients with acute coronary syndromes (unstable
angina pectoris/acute myocardial infarction). CRP and SAP
bindtheirrespectiveligandsinacalcium-dependentmanner.
Both of them play important roles in innate resistance to
microbes and in scavenging pathogenic cellular debris in-
cluding extracellular matrix components [9]. Pentraxin
3(PTX3)wasidentiﬁedintheearly1990sinhumanendothe-
lial cells and ﬁbroblasts as a TNF-α-o rI L - 1 β-inducible
mRNA and protein, respectively. IL-6 does not deal with
PTX3 production. Despite manifest similarities of action,
PTX3 diﬀers from its short associates in many basic aspects,
such as gene organization, chromosomal localization, cellu-
lar sources, inducing stimuli and the recognized ligands [10].
3. GeneticAspects of Pentraxin3
The human ptx3 gene is localized on the chromosome 3q
band 25. It is composed of three exons, the ﬁrst two of which
encode for the signal peptide and the N-terminal domain
(amino acids 18–179), respectively. The third exon encodes
for the C-terminal domain featuring the pentraxin signature
(amino acids 179–381) [11]. Immature myeloid dendritic
cells were supposed to be the prevailing cellular population
capable to produce PTX3. However, stimulus-induced PTX3
has been detected in other cellular populations, such as the
monocytes/macrophages, smooth muscle cells, kidney epi-
thelial cells, synovial cells, chondrocytes, adipocytes, alveolar
epithelial cells, glial cells, ﬁbroblasts, and, of course, in endo-
thelial cells [12]. PTX3 promoters contain enhancer-binding
elements which, during proteosynthesis, ﬁne-tune ﬁnal
impact of PTX3 on its target structures. The most prominent
ones are activator protein-1 (AP-1), nuclear factor-kappa B
(NF-κB), and selective promoter factor 1 (SP1) [13]. Brieﬂy,
AP-1 enhances basal transcription of PTX3, whereas the NF-
κB binding site is operative in the response to inﬂammatory
cytokinesTNF-αand/orIL-1β.Tissue-speciﬁcally,theabove-
mentioned transcription factors are complemented, in their
proteosynthesis-modulating activities, by enzymatic bio-
chemical pathways. In lung epithelial cells challenging acute
inﬂammation, PTX3 mRNA as such is induced by TNF-α;
nevertheless, PTX3 protein generation itself does not require
consequent NF-κB transcription. Instead, PTX3 is manufac-
tured by way of the c-Jun N-terminal kinase pathway [14].
In endothelial cells, expression of PTX3 is readily induced
by TNF-α and IL-1β. Thereafter, an acute cellular alteration
sets in, in which the endothelial cell is converted from a
quiescent, anti-inﬂammatory phenotype, to a procoagulant
and proinﬂammatory cellular surface. This is the case in sep-
sis/infection or in acute myocardial infarction. On the otherMediators of Inﬂammation 3
hand, endothelial cells are implicated in low-grade sterile
inﬂammation that underlies atherosclerosis and small vessel
vasculitides. A counter-regulatory pathway which abrogates
unwanted inﬂammation is carried out by high-density lipo-
protein 3 (HDL3) subfraction. This HDL3-controled PTX3
production evades classical regulatory mechanisms in that it
relies on the activation of the PI3K/Akt pathway via G-cou-
pled lysosphingolipid receptors. The lysosphingolipid recep-
tor S1P, which is the one responsible for this alternative
PTX3 synthesis, is a protein particle carried by HDL3. In
human endothelial cells, therefore, PTX3 accomplishes dual
outcomeaccordingto therespective activators:(i)aninﬂam-
matory eﬀect induced by TNF-α and/or IL-1β or (ii) an
anti-inﬂammatory eﬀect induced by S1P/HDL3. The latter
is further translated into increased NO-dependent vasore-
laxation, endothelial cell antiapoptotic eﬀects, and increased
TGF-β expression with ensuing atheroprotective modulation
[15]. PTX3 generation is also regulated in a cell-dependent
manner by glucocorticoid hormones (GHs). GHs support
the production of PTX3 in ﬁbroblasts and endothelial cells,
whereas they suppress PTX3 production by haematopoietic
cells (dendritic cells and macrophages). Accordingly, in-
travenous administration of a glucocorticoid hormone
increases blood levels of PTX3 [16].
4. Pentraxin3 Storage in Neutrophils
Apart from the generation of PTX3 in a response to inﬂam-
matory stimuli, there is also a constitutive, ready-made form
of PTX3 which is stored in speciﬁc (lactoferrin+) granules of
neutrophils. After these cells have been activated by appro-
priate stimuli, this preformed amount of PTX3 is released
into the extracellular space. This is a virtually mature, that
is, glycosylated form of monomeric PTX3 which, once oc-
curring extracellularly, assembles into multimers of ﬁve sub-
units. The PTX3 glycosidic moiety presents a complex of bi-,
tri-, and tetra-antennary sialylated structures, the relative
number of which undergoes changes reﬂecting the inﬂam-
matory conditions in which actual PTX3 protein has been
generated. Glycosylation of PTX3 seemingly functions as a
ﬁne-tuning mechanism of the mature protein. Thus, neu-
trophils represent a ready-to-use reservoir of PTX3 guaran-
teeing its early release and early activity in acute inﬂamma-
tion [17]. Under normal steady-state conditions, circulating
neutrophils exhibit a short half-life terminated by apoptotic
death, which serves to protect the host from any undue
damage inﬂicted by these cells. Whenever inﬂammation is
evoked, those stimuli which account for early PTX3 release
delay concomitantly neutrophil apoptotic death. This is a
natural feedback mechanism maintaining neutrophil num-
bers within required limits; otherwise, the host would incur
premature neutrophil exhaustion leading to attenuation of
inﬂammation.Delayedneutrophilapoptosisisnotaselective
mechanism.Prolongedneutrophillife-spanisneededtosup-
port the host protection against infection/sepsis. However,
the same scenario, albeit occurring in a slow step-by-step
manner, is set in motion in chronic sterile inﬂammation
in which increased numbers of activated neutrophils are
harmful to the host. Atherosclerosis may serve as an example
thereof, although participation of neutrophils in this process
was long underestimated [18].
Upon inﬂammatoryactivation, neutrophils releaseabout
25% of their actual PTX3 content. Part of the extruded pro-
tein remains associated with the parent cell by way of neu-
trophil extracellular traps (NETs). This is a chromatin mate-
rial assembled with nuclear proteins which has been set
free concomitantly with PTX. Localization of PTX3 in neu-
trophil extracellular traps contributes to the generation of
an antimicrobial microenvironment which augments local
capacity to trap and kill microbes. Given the abundance of
neutrophils both in the circulation and in the inﬂammatory
foci, these cells whose life-span has been prolonged into the
bargain constitute the main source of PTX3 right after the
onset of infection or in acute sterile inﬂammation, such as
myocardial infarction. Neutrophil-released PTX3 is func-
tionallycompetentwellbeforedenovosynthesisbyothercells
delivers supplemental amounts of the protein. At the same
time, neutrophil-derived PTX3 accounts for another feed-
back mechanism which restricts excess transmigration of
activated neutrophils into the host’s tissues, thus dampening
unwanted dissemination of inﬂammatory reactions [19].
5. Regulation of Pentraxin3 Production
Activation stimuli which control PTX3 synthesis and release
canbeenumeratedasfollows:(i)proinﬂammatorycytokines
(IL-1β,T N F - α), (ii) TLR agonists, namely lipopolysaccha-
ride (LPS), (iii) distinct microbial moieties (OmpA, lipoara-
binomannans), and/or (iv) some intact microorganisms.
Taking into account the complexity of the inﬂammatory/
immune reactions, more than one stimulus is usually
employedtosetoﬀPTX3production.Toinitiatetheimmune
response, cell-expressed receptors tightly cooperate with
their ﬂuid-phase counterparts after they have recognized
hostile microorganisms (non-self) via the latter’s PAMPs.
Essentially, the same scenario proceeds in cases of sterile
inﬂammation, after the recognition machinery has discrimi-
nated own modiﬁed or damaged cell structures (altered self)
[20]. To give an example, macrophage scavenger receptor
CD36mediatesbindingandinternalizationofGram-positive
bacteria by cooperating with toll-like receptors TLR2 and
TLR6, thereafter initiating production of proinﬂammatory
cytokines TNF-α,I L - 1 β,I F N - γ, and many others.
Concurrently, production of both short and long pentraxins
CRP and PTX3 by their paternal cells may be started oﬀ.I n
contrast to the current paradigm which claims that cytokines
considered proinﬂammatory should be activated to start the
inﬂammatory/innate immunity response, IFN-γ downreg-
ulates PTX3 production in dendritic cells and in monocyte-
macrophage cell lines. To achieve this, IFN-γ decreases
PTX3 mRNA transcription and reduces PTX3 transcript
stability, respectively [21]. On top of it, LPS-induced
PTX3 expression is downregulated by (i) interleukin-4, (ii)
1α,25-dihydroxivitamin D3, and (iii) prostaglandin E2 [22].
Additionally, PTX3 by itself does not bind to (i) lipopolysac-
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A, and B, (iv) exotoxin A and (v) N-acethylmuramyl-L-
alanyl-D-isoglutamine (MDP). Interleukin-(IL-)10, a most
prominent anti-inﬂammatory cytokine, enhances LPS-
induced PTX3 production, however, paradoxically it might
appear. Due to the impact of IL-10 on dampening inﬂam-
mation and supporting wound healing, this fact implies that
PTX3/IL-10wouldplayanimortantroleintissuerepair[23].
6.Pentraxin3inCardiovascularDiseases
Important pieces of knowledge regarding PTX3 behavior
in cardiovascular diseases, such as atherosclerosis and acute
myocardialinfarction(AMI),havebeengainedinthelastten
years. As early as in 2000, Peri and coworkers published in
Circulation theirresultsfromacohortof37patientswhohad
presented with an AMI. The authors showed that in these
patients, plasma levels of PTX3 peaked as early as ∼6h o u r s
after the onset of chest pain. Thus, maximal concentration
of PTX3 was available much earlier than that of CRP which
is achieved after ∼48 hours. In AMI patients, individual
levels of PTX3 were attained independently of the extent
of myocardial necrosis or incident heart failure assessed by
the Killip class [24]. Four years later, these authors extended
their original ﬁndings by adding that in AMI patients,
PTX3 supplied the most powerful information regarding
three-month mortality after the index event. In their study,
prognostic value of PTX3 was superior to that provided by
CRP, CK, TnT, and NT-proBNP [25]. Additional studies
introduced PTX3 as a prognostic biomarker in heart failure,
both acute and chronic, which was unrelated to an AMI
[26, 27]. In the cardiovascular health study, PTX3 has been
established to associate with the incidence of CAD and
all-cause mortality in CAD patients, independently of CRP
and other classical risk factors [28]. In our own study dealing
with plasma PTX3 changes in patients undergoing coronary
artery bypass grafting, we expectedly documented hundred-
fold elevations of CRP in all patients, none of whom suﬀered
any peri- or postoperative complication. However, PTX3 did
not exceed the level of 2ng/mL in any blood sample col-
lected during or up to the 7th day after the operation, this
respective value has been set as normal for healthy humans
[29]. Studies examining the metabolic syndrome, a prom-
inent risk factor of CAD, do also point out to discordant
comportment of CRP and PTX3. Whereas CRP appears
to correlate positively with (i) body weight, (ii) body-mass
index, (iii) waist circumference, (iv) fasting plasma glucose,
and (v) plasma IL-6 levels and negatively with (i) HDL cho-
lesterol and (ii) adiponectin, PTX3 displays the opposite
trends.Itcanbe soundlyassumedthatthefunctionsofPTX3
and CRP complement or even overlap in some situations,
wheres in others they diverge substantially. There are even
ﬁrst hints that PTX3 might play an as yet unrecognized
protective role in atherosclerosis and its complications [30].
7. Pentraxin3 in Atherosclerosis
Studies examining PTX3 in the process of atherogenesis
found this long pentraxin to be expressed in human vascular
smooth muscle cells via atherogenic lipoproteins [31], to up-
regulate tissue factor expression both in human endothelial
cells [32] and in activated monocytes [33], and to occur
extensively in advanced atherosclerotic plaques. Therein, the
sourceofPTX3isnotconﬁnedtomacrophagesandsurviving
endothelial cells [34], but, importantly, PTX3 is also present
in inﬁltrating neutrophils [35], a cell population increasingly
recognized as being active in the initial phase of the disease
as well as in its complications [36, 37]. Clinically, PTX3 has
been found to operate actively in unstable angina pectoris
[38, 39] and in restenosis after coronary artery stent intro-
duction; however, without identifying its source(s) in these
conditions [40]. Furthermore, PTX3 displays a predilection
to segments of vascular or synovial inﬂammation in rheu-
matic diseases, the pathogenesis of which is supposed to have
much in common with that of atherosclerosis [41]. As it is,
the inaugural question stands out with an intriguing acuity:
is pentraxin 3 an inﬂammatory/harmful or an anti-inﬂam-
matory/beneﬁtial mediator?
This question has been partly resolved with the accession
of genetically modiﬁed mice in whom the PTX3 gene has
been silenced (ptx3−/− mice). These animals do not produce
any traces of PTX3 protein. When cross-bred with apolipo-
protein E gene-deﬁcient (apoe −/−) mice, which is a murine
phenotype closely recapitulating the development of human
atherosclerosis, mouse strains which result from these com-
binations (PTX3+/+ or PTX3+/− ApoE−/− versus PTX3−/−
ApoE−/−) yielded exciting insights into the involvement of
PTX3 in atherogenesis. During the course of aging, PTX3−/−
apoE−/− mice develop, in line with expectations, increasing
atherosclerosis as a function of time. When fed Western-type
diet, these mice display an even increased extent of athero-
sclerosis. In both settings, that is, normal chow versus West-
ern-diet-fed mice, PTX3 amounts correlated positively with
the atherosclerotic burden. By contrast, in PTX3+/+ apoE−/−
double knockout mice, the atherosclerotic aﬄiction is
unexpectedly enhanced instead of being diminished, which
should have been the case if PTX3 was an unequivocal ath-
erogenic mediator. Further studies speciﬁed that in athero-
sclerosis-prone mice, total absence of PTX3 was pronounced
in the vascular wall by increased upregulation of (i) proin-
ﬂammatory mediators such as the chemokines (e.g., CCL2,
CCL3, CCL5, CCL7, CCL8) or cytokines (e.g., IL-4, IL-6,
TNF-α), (ii) transcription factors such as NF-κB and the
related protein Irak1, Fos, Jun, GATA3, GATA4, Egr2, Egr3,
(iii) key mediators of the inﬂammatory response (e.g., TLR-
2, TLR-4), and/or (iv) adhesion molecules responsible for
the onset of endothelial dysfunction: intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), endothelial leukocyte adhesion molecule-1
(E-selectin), platelet/endothelial cell adhesion molecule
(PECAM) [42].
8.Pentraxin3 inMyocardialInfarction
andin Ischemia/Reperfusion Injury
Alberto Mantovani’s team furthermore evidenced that in ge-
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myocardial infarction, notably in the reperfusion phase. It
must be pointed out here that PTX3 is not expressed in
the heart under resting conditions, either murine or human.
During reperfusion of a previously ischemic myocardium
(or, practically, any tissue), an inﬂammatory response is elic-
ited by explosive production of reactive oxygen species. In
thecourseofreperfusion,aninjurydevelopswhichischarac-
terized by leukocyte activation and recruitment thereof into
the reperfused area; by endothelial dysfunction which paves
the way to these cells’apoptotic or necrotic death and/or by
c a r d i o m y o c y t ec e l ld e a t hw h i c ho c c u r sa sar e s u l to fb l o o d
ﬂow defects (the “no-reﬂow” phenomenon). In a model of
coronary artery ligation/reperfusion, PTX3−/− mice exhibit
more extensive myocardial damage compared to their wild-
type littermates. Speciﬁcally, reperfusion injury is mani-
fest as (i) increased activated neutrophil and monocyte/
macrophage inﬁltration to the damaged tissue, (ii) decreased
number of tissue capillaries including extension of the no-
reﬂow area by endothelial swelling which results in an
obstruction of the remaining vessels, and/or (iii) increased
numberofapoptoticcardiomyocytescausedeitherbymicro-
circulatory drop-outs, or inﬂicted to the cardiomyocytes by
activated complement. Conversely, administration of exoge-
nous PTX3 to PTX3-deﬁcient mice dampens this injury
down to the level experienced by their wild-type littermates.
Administration of surplus PTX3 protein seems to confer a
supplemental protection not only to the deﬁcient, but also
to normal, that is, PTX3+/+ mice [43]. As far as humans are
concerned, the situation requires much of further research.
9. Interactionof Pentraxin3 with
PlateletsinAcuteMyocardialInfarction
Activated platelets cause much of tissue damage in myocar-
dial infarction. Hence, they are the predominant target cells
of PTX3. Upon extrusion into the extracellular space,
neutrophil-originating PTX3 binds to adjacent platelets
which, thereupon, lose much of their robust inﬂammatory
armamentarium. PTX3-stained platelets are thereafter resis-
tant to the formation of platelet-platelet homoaggregates
or to platelet-neutrophil or platelet-monocyte heteroaggre-
gates. Furthermore, PTX3 broadly impacts the adhesion
molecule P-selectin, which is known to play distinct roles
in atherogenesis. PTX3 brings about downregulation of P-
selectin-dependent neutrophil recruitment to inﬂammatory
sites and of P-selectin-induced cellular heteroaggregate for-
mation. Hence, decreased numbers of microaggregates are
present that would impair blood ﬂow in the microcircula-
tion, not to speak of their additional noxious potential. In
acute coronary syndromes, the overall procoagulant state is
increased, including excess tissue factor formation by diﬀer-
e n tc e l lt y p e sw h i c hm a k e st h eb l o o dm o r e“ s t i c k y ”[ 44].
Intervention of either endogenous or exogenous PTX3
mitigates the development of the “no-reﬂow” fenomenon,
that is, sustained tissue hypoxia/anoxia despite successful
recanalization of large arteries. The jeopardized tissue is
imbibed, irrespective of its extent, by a dense inﬁltrate
which is composed largely of granulocytes and macrophages.
The same applies to the early necrotic scar before its
ﬁbrotic transformation. PTX3 can be detected in most of
the inﬁltrating macrophages and remaining endothelial cells,
whereas neutrophils are scarcely found by this time point. If
so,afewgranulocytesarelocalizedmainlyinthecenterofthe
lesion, whereas in the outer parts, PTX3 is found only extra-
cellularly. Cardiomyocytes are constantly devoid of PTX3
[45]. On the subcellular level, activities of PTX3 impact the
transcription factor NF-κB and its modifying eﬀects on pro-
teosynthesis,sincethebeneﬁcialoutcomeislostinIL-1RI-or
MyD88-deﬁcient mice. MyD88 is a cellular adaptor protein
downstream of the receptors for TLR and IL-1R. MyD88- or
IL-1R-deﬁcient mice are unable to upregulate PTX3 expres-
sionandincasesofacutecoronaryevents,theseartiﬁcialani-
mals behave like those who are entirely lacking the long pen-
traxin (PTX3-deﬁcient or PTX3−/− mice). Thus, the IL-1R-
MyD88pathwayplaysadominant roleinptx3mRNAinduc-
tion in heart ischemia. In MyD88- or IL-1R-deﬁcient mice,
amplePTX3proteinmaybeavailable,butPTX3-bornesignal
cannotbetransmittedfromthesurfacemembraneofthetar-
getcelltoitsnucleuswhereproteosynthesiscontroledbyNF-
κB takes place, including that which should supply, among
other mediators, more amounts of PTX3 protein [46].
In vitro, preincubation of apoptotic cells with PTX3
enhances complement factor C1q binding and factor C3
deposition on the cellular surface, thus mimicking par-
ticipation of PTX3 in complement-mediated clearance of
apoptotic cells. The in vivo a c t i v i t yo fP T X 3 ,h o w e v e r ,i s
dichotliomous, depending upon whether complement has
been activated systemically in circulating blood or locally
in the inﬂammatory focus. Furthermore, PTX3 binds to
late apoptotic neutrophils and inhibits their phagocytosis by
monocyte-derived macrophages. Consequently, PTX3−/−
mice display increased C3 deposition in their ischemic myo-
cardium, whereas exogenous PTX3 reduces in them com-
plement activation, provided, of course, that the IL-1R-
MyD88 pathway is intact. In vitro, inhibition of complement
by ﬂuid-phase PTX3 occurs at concentrations in the same
range as those achieved in PTX3−/− mice 24 hours after
myocardial reperfusion. Therefore, it can be expected that
PTX3 protective activities in later phases of an AMI result
from its impact on the complement cascade, which accounts
for the salvage of apoptosis-destined, but still viable cells
[47].
10. Pentraxin3 Interactionwith
the Complement System
PTX3 is composed of a unique N-terminal region coupled
to a C-terminal domain, which is homologous to the short
pentraxins CRP and SAP. The N-terminal region of PTX3
is unrelated to any protein structure known so far. Studies
carried out with recombinant preparations of the N- and C-
terminal domains of PTX3, respectively, indicate that the N-
terminal region binds ligands such as (i) ﬁbroblast growth
factor-2 (FGF2), (ii) inter-α-inhibitor, and/or (iii) conidia of
A. fumigatus; whereas the pentraxin-like C-terminal domain
of PTX3 interacts with the complement factor C1q and
the adhesion molecule P-selectin. On the other hand, both6 Mediators of Inﬂammation
the N- and the C-terminal domains have been implicated in
the interaction with the complement factor H [48].
The impact of PTX3 on complement activation is a
complex issue. PTX3 binds C1q, the ﬁrst component of
the classical complement cascade, by interacting with the
C1q globular head (gC1q) and, in particular with charged
residues on the apex part of the molecule which encompass
all three C1q chains (i.e., gC1qA, gC1qB, and gC1qC) [49].
PTX3 binds to immobilized C1q, such as is aggregated on the
surface of bacterial walls. Interaction of PTX3 with surface-
bound C1q leads to the activation of the classical pathway, as
can be assessed by the deposition of C3 and C4 fragments
on the target cells. PTX3 itself, however, does not interact
either with C3 or with C4. In contrast, the presence of PTX3
in circulating blood leads to a dose-dependent inhibition of
C1q hemolytic activity, an event in which PTX3 limits C1q
binding to antibody-sensitized erythrocytes. Hence, binding
of ﬂuid-phase PTX3 to free C1q results in the inhibition of
the classical cascade of complement. As it is, PTX3 exerts a
dual role on the classical pathway of complement: it supports
clearance of corpuscular material that binds PTX3, such
as microbes or apoptotic cells, while it restricts unwanted
complement activation in circulating blood [50].
The short pentraxin CRP, in addition to the classical
pathway, modulates the alternative pathway of complement
via interaction with factor H, the main soluble regulator of
thealternativepathway.PTX3canalsointeractwithfactorH,
thusleading toincreasedfactorHandfactoriC3b deposition
on apoptotic cells. Factor iC3b is the prevalent opsonin
generatedduringcomplementactivation,whichperformsan
important activity in the process of complement-mediated
phagocytosis. The net result of PTX3 impact on the alterna-
tive pathway of complement is mirrored by increased factor
H deposition on PTX3-coated surfaces, that is, activation of
complement by the alternative pathway in response to ap-
propriate stimuli is increased. At the same time, however,
exaggerated complement activation by the alternative path-
way, which is active even under steady-state conditions to
guarantee an immediate-early weapon in cases of sudden
bacterial intrusion and which might, in a pathogen-free en-
vironment, inﬂict an erroneous damage to the host, is being
held under control [51].
PTX3 interacts also with components of the lectin path-
way. The mannose binding lectin (MBL) binds PTX3 via its
collagen-likedomain.MBL/PTX3complexesrecruitC1qand
elicit C3 and C4 deposition on target cell surfaces, such as
those of Candida albicans. Phagocytosis thereof is mightily
enhanced. Furthermore, pentraxin 3 interacts with another
ﬂuid-phase PRM, namely, L-Ficolin (alternatively known as
ﬁcolin-2). Of note, ﬁcolin-2 has been shown to bind conidia
of Aspergillus fumigatus. This ﬁcolin 2-A.fumigatus interac-
tionissupportedbyPTX3andconversely,PTX3-A.fumigatus
binding is supported by ﬁcolin-2. PTX3 also promotes
ﬁcolin-2-induced complement deposition on the surface of
A. fumigatus, thus aiding the host to combat the infection
[52]. Recently, an interaction between M-ﬁcolin (ﬁcolin-1)
and PTX3 has been described in which immobilized PTX3
triggers M-ﬁcolin- induced activation of the lectin comple-
ment pathway [53].
11. Pentraxin3 Interactionwith
MicrobialMoieties
Opsonization of target cells (invading pathogens or altered
self structures) results in (i) facilitated pathogen recognition
(and increased phagocytosis and killing) and in (ii) innate
immune cell activation (and increased inﬂammatory cytok-
ine and nitric oxide production). Moreover, opsonization by
PTX3 is evidently linked to the activation of an appropriate
adaptive immune response (i.e., dendritic cell maturation
and polarization). PTX3 opsonizes manifold pathogens or
pathogen-derived ligands, most importantly zymosan, Para-
coccidioides brasiliensis or conidia of Aspergillus fumigatus
[54]. Other interactions concern Gram-positive and Gram-
negative bacteria, namely, Staphyloccocus aureus, Pseudomo-
nas aeruginosa, Salmonella typhimurium, Streptococcus pneu-
moniae, and Neisseria meningitidis. Even viruses are aﬀected,
namely, human and murine cytomegalovirus (CMV) or
H3N2 inﬂuenza virus.
PTX3 binds the outer membrane protein A from Kleb-
siella pneumoniae (KpOmpA). OmpA, an archetypical path-
ogen-associated molecular pattern, is a prominent mem-
branecomponentofGram-negativebacteria,whichhasbeen
conserved in phylogeny among the enterobacteriaceae family.
As such, KpOmpA is recognized by monocytes and dendritic
cells (DCs) via two members of the scavengerreceptor family
(the lectin-like oxidized low-density lipoprotein receptor-1 or
LOX-1 and the scavenger receptor expressed by endothelial
cell-I or SREC-I) and is able to induce a TLR2-dependent
proinﬂammatoryresponse[55].Thisinﬂammatoryresponse
includes supplemental PTX3 production via a positive feed-
back loop which, in its turn, promotes the original inﬂam-
matory response brought about by KpOmpA, in terms of in-
ﬂammatory cell recruitment and inﬂammatory cytokine
release. Due to PTX3 participation, this response is comple-
ment modiﬁed [56]. In murine Klebsiella pneumoniae infec-
tion, the diﬀerence between death and recovery relies on
PTX3-evoked ﬁne-tuning of the balance between tumor
necrosis factor (TNF-α) and nitric oxide (NO) production.
By (i) shifting the balance of these antagonistic mediators in
one or another way and (ii) depending upon the inaugural
inﬂammatory response which must deal either with a high
or a low bacterial inoculum, PTX3 will either favor or dis-
favor the ability of the host to combat the infection [57].
Essentially, these principles hold true for any inﬂammation,
be it of microbial or sterile origin. Examples thereof will be
presented followingly.
12.Pentraxin3 andImmuneResponses in
Aspergillus Fumigatus Infection
Aspergillus fumigatus is an ubiquitary fungus which elicits
a broad spectrum of diseases in immunocompromised or
atopic subjects, ranging from severe pulmonary infections to
allergy. Aspergillosis is a major life-threatening infection in
patients with defective phagocytosis, the hallmark of chemo-
therapy- or radiotherapy-induced neutropenia and mono-
cytopenia [58]. From among inborn immunodeﬁciencies,Mediators of Inﬂammation 7
chronic granulomatous disease (CGD) is of interest in this
context. Pathophysiologically, this condition displays defec-
tive superoxide production by the enzyme NADPH. The
clinical course is characterized by increased susceptibility to
infections. Opportunistic pathogens such as Aspergillus fu-
migatus are involved. Prophylaxis with trimethoprim-sulfa-
methoxazole, itraconazole, and, in selected cases, adminis-
tration of IFN-γ may be eﬃcient, but often imperfect. Exces-
sive inﬂammation is treated with systemic corticosteroids
which, however, further suppress the patient’s immunity.
Gene-replacement therapy for patients lacking a suitable
stem cell donor is still an experimental procedure. Neu-
trophils, although reduced in numbers and/or in function,
are of paramount importance in the institution of a protec-
tive inﬂammatory response. Inﬂammation by itself may con-
fer some protection. Notwithstanding, tight control of de-
fense reactions is a vital condition. Unleashed inﬂammation
is deleterious. On top of these problems, CGD patients may
develop autoimmune diseases, a condition which mirrors
generation of neoantigenic determinants, presumably by
reactive oxygen and nitrogen species, which is the more so
astonishingthattheNADPHenzymeisfunctionallydeﬁcient
[59].
In mice, genetic loss-of-function studies have yielded
results that might be, at least in part, applied to humans.
First, PTX3-knockout mice (ptx3−/−), in whom the gene
encoding for PTX3 has been silenced, are highly susceptible
toinvasivepulmonaryaspergillosis.Thecourseofthedisease
recapitulates defective recognition and killing of aspergillus
conidia by PTX3-deﬁcient neutrophils, dendritic cells, and
alveolar macrophages [60]. Second, the p47phox−/− mice
closely mimic human CGD, most importantly the defective,
albeit detrimental inﬂammation. Once these mice have been
infected with Aspergillus fumigatus, their own production
of PTX3 is both delayed and insuﬃcient. Administration of
exogenousPTX3inearlyinfectionisabletorescueantifungal
resistance and, at the same time, to restrain the exaggerated
inﬂammatory response to the fungus by way of curbing the
IL-23/Th17inﬂammatoryaxis[61].Thisbeneﬁcialreversalis
produced via downregulation of IL-23 production by den-
dritic cells and epithelial cells, an eﬀect associated with
limited expansion of IL-23R+γδ+ T cells. These cells are
important producers of IL-17A, a mighty inﬂammatory cy-
tokine and a neutrophil chemoattractant which is involved
in many inﬂammatory diseases, once again either microbial
(e.g., Borrellia burgdorferi, Mycobacterium tuberculosis)o r
sterile (atherosclerosis including its complications) in ori-
gin. Consequently to IL-17A decrease, protective Th1/Treg
responses are upregulated [62].
To elucidate this positive point of return, it should be
reminded that defective tryptophan catabolism contributes
to excessive inﬂammation in CGD individuals infected with
Aspergillus fumigatus. In immunocompetent hosts, trypto-
phan metabolism regulates both antimicrobial resistance
and tolerance to inﬂammation-inducing microbial stimuli.
Since superoxide is a cofactor of IDO, which is the rate-
limiting enzyme in tryptophan degradation, superoxide-
induced activation of IDO is a central mechanism by which
an equilibrium between antifungal resistance and immune
tolerance is achieved. The enzyme IDO represents both the
host’s eﬀector defense mechanism and a means of properly
balancing the generation of inﬂammatory Th17 and reg-
ulatory Tc e l l s( T regs)[ 63]. Tregs and IL-17-producing Th17
cells call forth opposing responses in inﬂammation, includ-
ing aspergillosis. Whenever harmful inﬂammation predom-
inates, whether microbial or sterile in origin, this IL-17-
driven inﬂammation is associated with a decrease in anti-
inﬂammatory Treg cellular responses [64]. Basically, the same
holds true for invasive aspergillosis as well as for human is-
chemia-reperfusion injury, no matter which organ is aﬀected
[65]. In all these cases, an attempt at a defense reaction
translates into a control-evading detrimental inﬂammation.
In terms of cellular adaptive immunity, expression of mRNA
for transcription factors Tbet/Foxp3, which is indicative of
Th1/Treg activation, is increased in CD4+ T cells from wild-
type, disease-resistant mice. Conversely, RORγt/Gata3 tran-
scription factor mRNA expression, which is indicative of the
opposite Th17/Th2 activation, is increased in CD4+ Tc e l l s
fromdisease-pronep47phox−/− mice.Earlyadministrationof
PTX3top47phox−/− micerestoresthismalevolentbalancein
that it reverses the original ratio of the transcription factors:
it increases the expression of Tbet/Foxp3 and decreases that
of RORγt/Gata3 [66]. It is tempting to speculate that com-
parable eﬀects of PTX3 would be operative in patients with
myocardial infarction, but reliable proofs thereof are as yet
lacking.
13.AcquiredCellularImmunity
in Inﬂammation
It is well established that CD4+T cells take part in the
pathogenesis of atherosclerosis [67]. In addition to classical
Th1a n dT h2 helper cellular subsets, each producing its own
set of cytokines which are mutually antagonistic, a third sub-
set has been described recently, namely, the Th17 cells
[68, 69]. These cells express proinﬂammatory cytokines of
their own. The most important of them has been named
interleukin- (IL-)17. Actually, IL-17 is a common denom-
ination for a set of closely related cytokines referred to as
IL-17A to IL-17F, respectively. From the clinical point of
view, IL-17A and IL-17E appear to be the most active ones
[70]. The orphan nuclear receptor retinoic acid-related or-
phan receptor γt (RORγt) has been proposed as the key
transcription factor for the diﬀerentiation of the Th17 line-
age [71]. Th17 cells have been shown to play a role in chronic
inﬂammation which, historically, was attributed to Th1
cells. One of these conditions is atherosclerosis [72]. Recent
studies found that Th17 cells and their eﬀector cytokine
IL-17 are really increased in peripheral blood of patients
with atherosclerosis, including acute coronary syndromes
[73, 74]. Pathophysiologically, the Th17/IL-17+ cells directly
support the development of atherosclerosis in ApoE−/−
mice. Herein, the amount of Th17 cells and of RORγti n
aﬀected vessels is proportional to the magnitude of the over-
all atherosclerotic burden. Both mediators are not manu-
factured in situ, as can be inferred by their respective8 Mediators of Inﬂammation
behavior in ApoE−/− mice. The number of Th17 cells in
spleens of young, not yet atherosclerotic ApoE−/− mice,
has been proved comparable to that in healthy control ani-
mals. In ApoE−/− mice, the number of Th17 cells tended to
increase as a function of time, tightly paralleling continuing
development of atherosclerosis. Although CD4+ T cells are
the main source of IL-17, they are not the only origin of this
cytokine. Neutrophils, as well as the CD8+ and γδ+ T cells,
were demonstrated to generate IL-17 in response to the in-
ﬂammatory cytokine IL-15, just to give an example. Dif-
ferentiation of mature Th17 cells depends on the stimulation
with a “cocktail” of cytokines, namely, IL-6, TGF-β,a n d
IL-21 and on the induction of their inherent transcription
factor RORγt. On the other hand, IL-23 is indispensable to
the achievement of mature Th17 phenotype and its stability
under inﬂammatory conditions [75, 76].
The Th17/Treg equilibrium is vital to the control of
inﬂammation [77, 78]. Its derangement will bring about
destabilization of atherosclerotic plaques, the composition
of which has been extended recently to include Th17 cells,
the cytokine IL-17A, and the transcription factor RORγt.
If the fragile Th17/Treg balance is lost, its new inadvertent
ratio will call forth the onset of acute coronary syndromes
(instable angia pectoris or acute myocardial infarction).
In this context, patients experience signiﬁcant increase in
peripheral blood Th17 cell numbers, Th17-related cytokines
(IL-17A, IL-6, IL-23) and RORγt levels. At the same time,
there is a decrease in blood levels of Treg numbers and
Treg-related cytokines IL-10 and TGFβ as well as of their
transcription factor FoxP3. It may be soundly hypothesized
thatPTX3,whichisendowedwiththecapacitytoreversethis
harmful inﬂammatory dysbalance in Aspergillus fumigatus
infection by skewing the predominance of transcription
factors (RORγt/Gata3 → Tbet/Foxp3) with consequent shift
of their respective cellular subsets (Th17/Th2 → Th1/Treg),
might bring about a comparable beneﬁcial eﬀects in this
form of sterile inﬂammation. Nevertheless, it must be
strongly pointed out that results yielded by experimental
animals cannot by dogmatically extrapolated to humans, as
attractive as they may appear [79].
14. Concluding Remarks
In both acute infections and acute coronary syndromes,
the role of PTX3 appears to be primarily protective in that
the long pentraxin dampens the inappropriate, exaggerated
inﬂammatory response. On the local level, PTX3 released by
PMNs or produced by monocytes/macrophages will abolish
neutrophil recruitment and oxidative burst, a condition
whichkillsbacteriabyreactiveoxygenspecies,whileitinﬂicts
collateral damage to the host. PTX3 co-operation with the
adaptive immune system in defense inﬂammation which
combats infection supports, in its turn, development of a
protective Th1/Treg immune response while at the same time
it limits harmful inﬂammation elicited by the Th17/Th2
immune response. Further studies are needed in this context
tofurnishdatathatwouldimplytowhichextentPTX3might
be employed therapeutically.
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